Mark Ostroot

This paper describes the discovery and validation of C273, a mitochondrial complex I modulator that reduces Alzheimer's disease pathology by enhancing cellular resilience through AMPK-mediated pathways.

The paper assesses a novel mitochondrial complex I inhibitor, C458, in vitro and in vivo, showing it protects against Aβ toxicity, improves brain energetics, and reduces inflammation in Alzheimer's disease models.

This study shows that reducing mitochondrial complex I activity in mice induces AD-like transcriptomic changes, which are partially reversed by a complex I inhibitor.

This study shows that inhibiting mitochondrial complex I with CP2 reduces pTau levels and improves cognitive and metabolic function in 3xTg-AD mice.